BRD2 and hyperprolactinemia: Increased risk of insulin resistance (OR 1,63, CI 0.99–2.66, p = 0.0507) in the subgroup of women with PCOS with TSH > 2.5 regardless of ATA status, elevated risk of hypercholesterolemia (OR 1.7, CI 0.95–3.05, p = 0.07) and hyperprolactinemia (OR 1.84, CI 0.94–3.62, p = 0.07) in the subgroup of women with TSH > 2.5 and negative ATA and an increase in the likelihood of LH/FSH > 2 in the subpopulation of women with TSH > 2.5 and positive ATA (OR 4.43, CI 0.99–19.79, p = 0.051) was noticeable but did not reach statistical significance (Table 3).